10-Q: AccuStem Sciences Q3 Loss Widens Amid R&D Boost, Funding Search

AccuStem Sciences reported increased net losses in Q3 2025, driven by higher R&D and administrative costs, while actively seeking new equity financing to address critical liquidity concerns.

Summary

• Net loss for the three months ended September 30, 2025, was $399,897, an increase from $328,174 in the prior year period.
• Net loss for the nine months ended September 30, 2025, was $1,241,708, up from $1,133,001 in the same period last year.
• Research and development expenses surged by 132% to $72,720 for the three months and 67% to $161,270 for the nine months ended September 30, 2025, primarily due to patent-related expenses, laboratory work, and consulting.
• General and administrative expenses increased by 10% to $327,177 for the three months and 6% to $1,080,438 for the nine months ended September 30, 2025, mainly due to public relations and professional fees.
• The company reported an accumulated deficit of $9,268,755 and a working capital deficit of $2,910,910 as of September 30, 2025.
• The cash balance as of September 30, 2025, was $14,391, which is deemed inadequate for current planned operations for at least the next 12 months.
• The company is actively pursuing additional equity financing, including private investment and public equity, to fund operations and R&D activities.
• Disclosure controls and procedures were not effective as of September 30, 2025, due to material weaknesses in internal controls over financial reporting, specifically a lack of accounting resources and inadequate monitoring.

Sentiment

Score: 3

Explanation: The company faces severe liquidity issues, with insufficient cash for the next 12 months and a growing accumulated deficit. While R&D is increasing and product development milestones are being met, the material weakness in internal controls and heavy reliance on related party funding are significant concerns. The need for substantial capital raises introduces considerable uncertainty.

Positives

• Cash balance increased to $14,391 as of September 30, 2025, from $5,046 at December 31, 2024.
• Total current assets significantly increased to $1,573,247 as of September 30, 2025, from $50,433 at December 31, 2024, largely due to $1,500,000 in advances paid for an intangible asset acquisition.
• Net loss per share improved to $(0.02) for the three months and $(0.08) for the nine months ended September 30, 2025, compared to $(0.03) and $(0.10) respectively in the prior year, due to an increased weighted average common shares outstanding.
• The company has achieved the milestone of partnering with a commercial laboratory, EmeritusDx, for MSC test processing.
• Management is actively pursuing additional equity financing to address capital needs.

Negatives

• Net loss increased by 22% to $399,897 for the three months ended September 30, 2025, and by 14% to $1,241,708 for the nine months ended September 30, 2025.
• Accumulated deficit grew to $9,268,755 as of September 30, 2025.
• Working capital deficit stood at $2,910,910 as of September 30, 2025.
• The cash balance of $14,391 as of September 30, 2025, is considered inadequate to support operations for at least the next 12 months.
• Total current liabilities significantly increased to $4,484,157 as of September 30, 2025, from $3,364,075 at December 31, 2024.
• Related party payables increased substantially to $3,366,503 as of September 30, 2025, from $2,370,259 at December 31, 2024, indicating heavy reliance on related party funding.
• Net cash used in operating activities increased to $872,746 for the nine months ended September 30, 2025, from $664,480 in the prior year, indicating higher cash burn.
• Disclosure controls and procedures were not effective as of September 30, 2025, due to material weaknesses in internal controls over financial reporting.

Risks

• The company has incurred a net loss in every fiscal period since inception and anticipates operating losses to continue for the foreseeable future.
• Insufficient cash and current assets to support operations through at least 12 months from the issuance date of the financial statements.
• No assurance that additional financing will be available when needed, if at all, or on favorable terms and conditions.
• Inability to obtain sufficient funding could force delays, reductions, or elimination of research and development programs and product portfolio expansion.
• The success, cost, and timing of clinical development of products, including preclinical and clinical trials of StemPrintER and MSC, are uncertain.
• Ability to obtain and maintain regulatory approval of product candidates, and any related restrictions, limitations, or warnings, is a risk.
• Competition from companies currently marketing or developing treatments for target indications.
• The rate and degree of market acceptance and clinical utility of product candidates are uncertain.
• Reliance on collaborations and partnerships with third parties.
• Estimates regarding the potential market opportunity for product candidates may not be accurate.
• Ability to establish and maintain arrangements for the manufacture of product candidates.
• Intellectual property position and potential for patent litigation.
• Dependence on key individuals.
• Impact of government laws and regulations.
• Material weakness in internal controls over financial reporting due to a lack of accounting resources, inadequate monitoring controls, and insufficient segregation of duties, which could lead to material misstatements not being prevented or detected.
• Future equity or convertible debt financings will dilute ownership interest, and debt/preferred equity financing may involve restrictive covenants.
• Raising funds through collaborations may require relinquishing valuable rights to technologies or future revenue streams.

Future Outlook

The company anticipates operating losses to continue for the foreseeable future due to ongoing research funding, product development, and commercialization expenses. It plans to launch its lead product candidate, the MSC test, for clinical use in early 2026, following the completion of laboratory transfer and CLIA certification, which is expected to take at least 18 months. The company is actively pursuing additional equity financing to fund its planned research and development activities and other expenditures, as its current cash and assets are insufficient for the next 12 months.

Management Comments

• Management believes that the Company does not have sufficient cash and current assets to support its operations through at least 12 months from the issuance date of these condensed consolidated financial statements, and will require significant additional cash resources to continue its planned research and development activities.
• The Company will need additional funds for promoting new products and working capital required to support research and development activities and generate sales from its products.
• Management intends to remediate this item [material weakness in internal controls] in the following manner: i. Recruit appropriately skilled accounting resources.
• We plan to launch our lead product candidate, the microRNA Signature Classifier (MSC) test, for clinical use in early 2026.
• We anticipate that it will take at least 18 months to complete these milestones [MSC commercialization steps].

Industry Context

AccuStem Sciences operates in the highly competitive and capital-intensive life sciences and cancer diagnostics industry, focusing on genomics-based personalized medicine for breast and lung cancer. The development of novel genomic tests like MSC and StemPrintER aligns with the broader industry trend towards precision medicine and early cancer detection. The market opportunity for lung nodule and early-stage breast cancer diagnostics is substantial, estimated at over $6.3 billion annually in the US, indicating a significant unmet need for more accurate and efficient patient care solutions. The company's strategy to offer additional commodity testing alongside its proprietary assays reflects a common approach to leverage existing infrastructure and diversify revenue streams in the diagnostics sector.

Comparison to Industry Standards

• The company's validation of MSC in multiple prospective, randomized cohorts representing over 5,000 patients and publication in top-tier journals like the Journal of Clinical Oncology demonstrates a commitment to rigorous scientific evidence, which is a high standard in the diagnostics industry for gaining clinical acceptance and reimbursement.
• StemPrintER's validation in large clinical cohorts, including approximately 2,400 patients from the European Institute of Oncology (IEO) and 800 patients from the TransATAC study, provides strong prognostic data, comparable to the robust evidence required for other leading genomic assays in oncology.
• The company's pursuit of U.S. CLIA certification for its tests is a standard regulatory pathway for commercializing Laboratory Developed Tests (LDTs) in the US, indicating adherence to established industry practices for quality and reliability.
• The stated need for significant additional capital and the ongoing operating losses are typical for early-stage life sciences companies engaged in extensive R&D and pre-commercialization activities, though the magnitude of the accumulated deficit and working capital deficit highlights a significant financial challenge compared to more established industry players.

Corporate Governance

Related Party Transactions

• Tiziana, a related party under common control, owns approximately 10.91% of the company.
• The company has a shared services agreement with Tiziana for management and administrative services, incurring $1,924 for the three months and $2,586 for the nine months ended September 30, 2025.
• A balance of $88,296 was due to Tiziana for shared services as of September 30, 2025.
• Tiziana paid $178,707 in expenses on behalf of the company as of September 30, 2025.
• Tiziana provided $3,066,500 in funding support as of September 30, 2025.
• Gabriele Cerrone, Chairman of the Board and largest shareholder, provides consulting services for a monthly fee of $5,500, with $33,000 due to him as of September 30, 2025.

Stakeholder Impact

• Shareholders: Potential for significant dilution from future equity financings. The increased net losses and accumulated deficit negatively impact shareholder value. The material weakness in internal controls could erode confidence.
• Employees: Continued R&D activities and product development plans suggest ongoing employment, but funding uncertainties could pose risks to job security if financing is not secured.
• Customers (future): The development of MSC and StemPrintER offers potential for improved cancer diagnostics, but delays in commercialization or failure to secure regulatory approvals could impact availability.
• Creditors: Increased related party payables and overall liabilities, coupled with significant liquidity concerns, indicate higher credit risk.
• Suppliers: The company's financial instability and reliance on external funding could impact its ability to meet payment obligations to suppliers.

Next Steps

• Continue planned research and development activities for MSC and StemPrintER.
• Actively pursue additional equity financing (private investment and public equity).
• Complete the transfer of the MSC test from its development laboratory to the commercial partner laboratory (EmeritusDx).
• Seek U.S. Clinical Laboratory Improvement Amendments of 1988 (CLIA) certification for MSC, anticipated to take at least 18 months.
• Launch the MSC test for clinical use in early 2026.
• Initially launch StemPrintER in the US and then expand to other markets.
• Offer additional commodity testing (e.g., next generation sequencing, IHC receptor status, hereditary gene panel) to augment value propositions.
• Validate and commercialize the StemPrint platform in a variety of different tumor types beyond breast cancer.
• Recruit appropriately skilled accounting resources to remediate material weaknesses in internal controls over financial reporting.

Key Dates

Recommendation

AccuStem Sciences presents a highly speculative investment with significant red flags. The company is in a critical financial state, explicitly stating it lacks sufficient cash for the next 12 months and has a substantial accumulated deficit. While R&D spending is increasing, indicating progress on product development, the company has no revenue and continues to incur significant losses. The disclosure of material weaknesses in internal controls over financial reporting is a severe governance concern, suggesting unreliable financial reporting. Heavy reliance on related party funding further complicates the financial picture. The need for substantial additional equity financing, with no assurance of availability or favorable terms, points to high dilution risk for existing shareholders and potential for operational curtailment. Given the severe liquidity issues, ongoing losses, governance concerns, and high execution risk for product commercialization, a seasoned investor would likely recommend a strong sell or avoid this stock.

Keywords

AccuStem Sciences, ACUT, 10-Q, Quarterly Report, Life Sciences, Genomics, Personalized Medicine, Cancer Diagnostics, Breast Cancer, Lung Cancer, MSC Test, StemPrintER, Clinical Stage, Biomarkers, MicroRNA, Oncology, SEC Filing, Financial Results, Net Loss, Liquidity, Going Concern, Equity Financing, R&D Expenses, Internal Controls, Material Weakness, OTCQB Venture Marketplace